Why is Alembic Pharma falling/rising?

As of 25-Aug, Alembic Pharmaceuticals Ltd. is currently priced at 984.65, reflecting an increase of 10.15 or 1.04%. The stock has shown positive momentum recently, gaining for the last two days with a total return of 1.83% during this period. It has outperformed its sector by 0.63% today and is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. However, despite these short-term gains, the stock has experienced a decline of 1.27% over the past month and a more significant drop of 7.03% year-to-date. The company has a low Debt to EBITDA ratio of 0.67, indicating a strong ability to service debt, while its attractive valuation and high institutional holdings at 20.42% suggest confidence from larger investors. Nonetheless, the stock's long-term growth prospects appear poor, with a -9.13% annual decline in operating profit over the last five years and a -10.49% return over the past year.
In the broader market context, Alembic Pharmaceuticals has outperformed the Sensex by 1.55% over the past week, as the benchmark index has only risen by 0.45%. However, the stock's performance over longer periods is concerning, as it has underperformed the Sensex year-to-date and over the past year. The overall market sentiment may be influenced by the company's flat results in June and declining operating cash flow, which could deter potential investors. Despite the recent uptick in price, the combination of falling investor participation and the company's struggles with long-term growth could weigh on future performance.